Limits...
Evaluation of reactive oxygen metabolites in patients with non-small cell lung cancer after chemotherapy.

Wakabayashi T, Kawashima T, Matsuzawa Y - Multidiscip Respir Med (2014)

Bottom Line: As a marker of reactive oxygen species, ROMs levels were measured using the d-ROMs test.Patients who responded to chemotherapy showed significantly decreased (p = 0.014) ROMs levels after chemotherapy, whereas patients who had stable disease or progressive disease showed no change in ROMs level (p = 0.387).NSCLC patients had significantly elevated ROMs levels before chemotherapy compared with normal healthy subjects.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285, Japan.

ABSTRACT

Background: The aim of this study was to evaluate the level of reactive oxygen metabolites (ROMs) after chemotherapy in patients with non-small cell lung cancer (NSCLC) and its association with response to treatment.

Methods: Fifty-eight untreated NSCLC patients and twenty-three healthy subjects were selected for the study. Patients received two courses of platinum-based chemotherapy and were evaluated for oxidative stress and treatment response. As a marker of reactive oxygen species, ROMs levels were measured using the d-ROMs test.

Results: ROMs level (mean ± standard deviation) before chemotherapy in NSCLC patients (416 ± 135 U.CARR) was significantly elevated (p = 0.016) compared to normal healthy subjects (320 ± 59 U.CARR). Patients who responded to chemotherapy showed significantly decreased (p = 0.014) ROMs levels after chemotherapy, whereas patients who had stable disease or progressive disease showed no change in ROMs level (p = 0.387).

Conclusions: NSCLC patients had significantly elevated ROMs levels before chemotherapy compared with normal healthy subjects. Chemotherapy may suppress ROMs production in responders but not in non-responders. ROMs level may be a predictor of clinical outcome in patients receiving chemotherapy for NSCLC.

No MeSH data available.


Related in: MedlinePlus

ROMs levels (U. CARR) in control subjects and in patients with non-small cell lung cancer before treatment. Data are expressed as mean ± SD. ROMs level was elevated significantly in patients before treatment compared with the control subjects (p = 0.016, unpaired t-test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4150680&req=5

Figure 1: ROMs levels (U. CARR) in control subjects and in patients with non-small cell lung cancer before treatment. Data are expressed as mean ± SD. ROMs level was elevated significantly in patients before treatment compared with the control subjects (p = 0.016, unpaired t-test).

Mentions: The control subjects consisted of 15 men (65.2%) and 8 women (34.8%), with a median age of 65.6 years (range, 47–81 years). Eighteen control subjects (78.2%) were current or former smokers and 5 control subjects (21.8%) had never smoked. There were no significant differences in age, gender ratio, and smoking habit between NSCLC patients and healthy controls. The ROMs level (mean ± SD) in NSCLC patients before treatment (416 ± 135 U. CARR) was elevated significantly (p = 0.016) compared with healthy controls (320 ± 59 U. CARR) (Table 2 and Figure 1).


Evaluation of reactive oxygen metabolites in patients with non-small cell lung cancer after chemotherapy.

Wakabayashi T, Kawashima T, Matsuzawa Y - Multidiscip Respir Med (2014)

ROMs levels (U. CARR) in control subjects and in patients with non-small cell lung cancer before treatment. Data are expressed as mean ± SD. ROMs level was elevated significantly in patients before treatment compared with the control subjects (p = 0.016, unpaired t-test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4150680&req=5

Figure 1: ROMs levels (U. CARR) in control subjects and in patients with non-small cell lung cancer before treatment. Data are expressed as mean ± SD. ROMs level was elevated significantly in patients before treatment compared with the control subjects (p = 0.016, unpaired t-test).
Mentions: The control subjects consisted of 15 men (65.2%) and 8 women (34.8%), with a median age of 65.6 years (range, 47–81 years). Eighteen control subjects (78.2%) were current or former smokers and 5 control subjects (21.8%) had never smoked. There were no significant differences in age, gender ratio, and smoking habit between NSCLC patients and healthy controls. The ROMs level (mean ± SD) in NSCLC patients before treatment (416 ± 135 U. CARR) was elevated significantly (p = 0.016) compared with healthy controls (320 ± 59 U. CARR) (Table 2 and Figure 1).

Bottom Line: As a marker of reactive oxygen species, ROMs levels were measured using the d-ROMs test.Patients who responded to chemotherapy showed significantly decreased (p = 0.014) ROMs levels after chemotherapy, whereas patients who had stable disease or progressive disease showed no change in ROMs level (p = 0.387).NSCLC patients had significantly elevated ROMs levels before chemotherapy compared with normal healthy subjects.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-shi, Chiba 285, Japan.

ABSTRACT

Background: The aim of this study was to evaluate the level of reactive oxygen metabolites (ROMs) after chemotherapy in patients with non-small cell lung cancer (NSCLC) and its association with response to treatment.

Methods: Fifty-eight untreated NSCLC patients and twenty-three healthy subjects were selected for the study. Patients received two courses of platinum-based chemotherapy and were evaluated for oxidative stress and treatment response. As a marker of reactive oxygen species, ROMs levels were measured using the d-ROMs test.

Results: ROMs level (mean ± standard deviation) before chemotherapy in NSCLC patients (416 ± 135 U.CARR) was significantly elevated (p = 0.016) compared to normal healthy subjects (320 ± 59 U.CARR). Patients who responded to chemotherapy showed significantly decreased (p = 0.014) ROMs levels after chemotherapy, whereas patients who had stable disease or progressive disease showed no change in ROMs level (p = 0.387).

Conclusions: NSCLC patients had significantly elevated ROMs levels before chemotherapy compared with normal healthy subjects. Chemotherapy may suppress ROMs production in responders but not in non-responders. ROMs level may be a predictor of clinical outcome in patients receiving chemotherapy for NSCLC.

No MeSH data available.


Related in: MedlinePlus